Kenneth F Culver

US Patent:

20040148218, Jul 29, 2004

Filed:

Jan 29, 2003

Appl. No.:

10/353437

Inventors:

Gregory Bovee - Great Falls VA, US
Kenneth Culver - Robins IA, US

Assignee:

APAC Customer Services, Inc.

International Classification:

G06F017/60

US Classification:

705/010000

Abstract:

Methods and systems for predicting sales based on historical telephone contact are provided. The telephone billing statements of a telemarketing company or other company include called telephone numbers, the time of the call, the length of the call and other information. Telephone numbers that are more frequently called and telephone numbers associated with longer call times may be more likely to accept solicitation and purchase products or services. The telephone billing statements do not include household or personal information, so are more likely to avoid violation of privacy and identity protection standards. The telephone billing statements also do not provide the original source of the telephone number, such as telephone numbers provided by a retail company for a campaign.

US Patent:

60457899, Apr 4, 2000

Filed:

Jul 13, 1994

Appl. No.:

8/274584

Inventors:

Kenneth W. Culver - Potomac MD
R. Michael Blaese - Rockville MD

Assignee:

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

International Classification:

A61K 4800
C12N 1500

US Classification:

424 9321

Abstract:

A method for treating an tumor involves the initial identification of the tumor as one displaying a "bystander effect," whereby in vivo transfer of a gene conferring sensitivity to chemotherapeutic agent affects both transformed and non-transformed tumor cells. Into a tumor thus characterized is introduced in situ a retroviral vector containing the sensitizing gene. The retroviral vector, which may replication-defective or replication-competent, can be introduced directly (if it is replication-competent) or can be provided by means of a packaging cell line. Treatment of the patient with the chemotherapeutic agent thereafter effects tumor regression when as few as 10% of tumor cells are transformed, while normal tissue is not damaged. The anti-tumor impact of the treatment can be increased when the transducing vector also encodes an immune response-enhance substance such as IL-2 or another cytokine.